PD‐1 blockade enhances the effect of targeted chemotherapy on locally advanced pMMR/MSS colorectal cancer

Abstract Background Patients with DNA mismatch repair‐proficient/microsatellite stable (pMMR/MSS) colorectal cancer (CRC), which accounts for 85% of all CRC cases, display a poor respond to immune checkpoint inhibitors (i.e., anti‐PD‐1 antibodies). pMMR/MSS CRC patients with locally advanced cancers...

Description complète

Détails bibliographiques

Auteurs principaux:	Fengyun Pei, Wan He, Yinghua Duan, Qijun Yao, Yandong Zhao, Xinjuan Fan, Shuai Liu, Haiyang Chen, Fang He, Tingzhi Liu, Jiaoting Chen, Yijia Zheng, Heping Li, Xiaofang Guo, Lishuo Shi, Li Ling, Yaoxu Chen, Jiapeng He, Miao Liu, Mengli Huang, Yuezong Bai, Jianping Wang, Meijin Huang, Jun Huang
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-06-01
Collection:	Cancer Medicine
Sujets:	colorectal cancer neoadjuvant treatment PD‐1 blockade pMMR/MSS
Accès en ligne:	https://doi.org/10.1002/cam4.7224
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!